Reviewer’s report

Title: The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy

Version: 1 Date: 12 July 2012

Reviewer: Chirag Shah

Reviewer’s report:

There are no major or minor revisions.
Discretionary Revisions: The authors present a cogent argument for the development of intravitreal PPAR alpha agonists. They should temper their predictions for the future given that if such intravitreal agents were developed, it is very possible they could not be administered with anti-VEGF agents within the same syringe (e.g., if the solutions precipitated when mixed), or perhaps anti-VEGF agents will not be necessary in the absence of macular edema, or perhaps PPAR alpha agonists will be delivered intravitreally by some other route (e.g., drug eluding pellet). The authors should make the distinction between anti-VEGF agents improving diabetic macular edema and neovascularization, and systemic PPAR alpha agents slowing progression of retinopathy and thus decreasing risk of edema or neovascularization.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests